OXFORD, England--(BUSINESS WIRE)--Oxular Limited, a clinical-stage retinal therapeutics company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced the appointment of James “Jim” Jogerst as chief business officer, who will lead the company’s business development strategy, and oversee its current and planned strategic partnerships. Mr. Jogerst joins Oxular from Rubius Therapeutics, where he served as chief business officer.
Dr. Asmus brings two decades of experience leading global clinical and translational research programs for both retinal and rare diseases